{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:04:36Z","timestamp":1767625476305},"reference-count":28,"publisher":"Pharmaceutical Society of Japan","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2014]]},"DOI":"10.1248\/bpb.b14-00201","type":"journal-article","created":{"date-parts":[[2014,11,30]],"date-time":"2014-11-30T23:35:50Z","timestamp":1417390550000},"page":"1866-1871","source":"Crossref","is-referenced-by-count":12,"title":["Is Hyperuricemia a Risk Factor for Arteriosclerosis? Uric Acid and Arteriosclerosis in Apolipoprotein E-Deficient Mice"],"prefix":"10.1248","volume":"37","author":[{"given":"Hirokazu","family":"Wakuda","sequence":"first","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women\u2019s University"},{"name":"Department of Pharmacokinetics and Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, School of Pharmaceutical Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Ikeda","sequence":"additional","affiliation":[{"name":"College of Environment and Disaster Research, Fuji Tokoha University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Tabuchi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Kinki University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasumitsu","family":"Akahoshi","sequence":"additional","affiliation":[{"name":"Life Science Research Institute, Kinki University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumasa","family":"Shinozuka","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women\u2019s University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizuo","family":"Yamada","sequence":"additional","affiliation":[{"name":"Center for Pharma-Food Research (CPFR), Graduate School of Pharmaceutical Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease: the NHANES I Epidemiologic Follow-up Study. <i>Am. J. Epidemiol.<\/i>, <b>141<\/b>, 637\u2013644 (1995)."},{"key":"2","unstructured":"2) Liese AD, Hense HW, L\u00f6wel H, D\u00f6ring A, Tietze M, Keil U, Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort: World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. <i>Epidemiology<\/i>, <b>10<\/b>, 391\u2013397 (1999)."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. <i>Hypertension<\/i>, <b>34<\/b>, 144\u2013150 (1999).","DOI":"10.1161\/01.HYP.34.1.144"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. <i>Heart<\/i>, <b>78<\/b>, 147\u2013153 (1997).","DOI":"10.1136\/hrt.78.2.147"},{"key":"5","unstructured":"5) Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. <i>Ann. Intern. Med.<\/i>, <b>131<\/b>, 7\u201313 (1999)."},{"key":"6","unstructured":"6) Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. <i>Ann. Epidemiol.<\/i>, <b>10<\/b>, 136\u2013143 (2000)."},{"key":"7","unstructured":"7) Yamamoto T. Definition and classification of hyperuricemia. <i>Nippon Rinsho<\/i>, <b>66<\/b>, 636\u2013640 (2008)."},{"key":"8","unstructured":"8) Terkeltaub R. Update on gout: new therapeutic strategies and options. <i>Nat. Rev. Rheumatol.<\/i>, <b>6<\/b>, 30\u201338 (2010)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>89<\/b>, 4471\u20134475 (1992).","DOI":"10.1073\/pnas.89.10.4471"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apoprotein E. <i>Science<\/i>, <b>258<\/b>, 468\u2013471 (1992).","DOI":"10.1126\/science.1411543"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. <i>Arterioscler. Thromb.<\/i>, <b>14<\/b>, 133\u2013140 (1994).","DOI":"10.1161\/01.ATV.14.1.133"},{"key":"12","unstructured":"12) Jawie\u0144 J, Nastalek P, Korbut R. Mouse models of experimental atherosclerosis. <i>J. Physiol. Pharmacol.<\/i>, <b>55<\/b>, 503\u2013517 (2004)."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Plump AS, Smith JD, Hayek T, Aalto-Set\u00e4l\u00e4 K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. <i>Cell<\/i>, <b>71<\/b>, 343\u2013353 (1992).","DOI":"10.1016\/0092-8674(92)90362-G"},{"key":"14","unstructured":"14) Engberding N, Spiekermann S, Schaefer A, Heineke A, Wiencke A, M\u00fcller M, Fuchs M, Hilfiker-Kleiner D, Hornig B, Drexler H, Landmesser U. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? <i>Circulation<\/i>, <b>110<\/b>, 2175\u20132179 (2004)."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Elion GB. Enzymatic and metabolic studies with allopurinol. <i>Ann. Rheum. Dis.<\/i>, <b>25<\/b> (Suppl.), 608\u2013614 (1966).","DOI":"10.1136\/ard.25.Suppl_6.608"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. <i>Ann. Intern. Med.<\/i>, <b>64<\/b>, 229\u2013258 (1966).","DOI":"10.7326\/0003-4819-64-2-229"},{"key":"17","unstructured":"17) Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? <i>Atherosclerosis<\/i>, <b>148<\/b>, 131\u2013139 (2000)."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. <i>Circ. Res.<\/i>, <b>70<\/b>, 593\u2013599 (1992).","DOI":"10.1161\/01.RES.70.3.593"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Inokuchi T, Tsutsumi Z, Takahashi S, Ka T, Yamamoto A, Moriwaki Y, Masuzaki H, Yamamoto T. Effects of benzbromarone and allopurinol on adiponectin <i>in vivo<\/i> and <i>in vitro<\/i>. <i>Horm. Metab. Res.<\/i>, <b>41<\/b>, 327\u2013332 (2009).","DOI":"10.1055\/s-0028-1102947"},{"key":"20","unstructured":"20) Ukkola O, Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities? <i>J. Mol. Med.<\/i>, <b>80<\/b>, 696\u2013702 (2002)."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) D\u00edez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. <i>Eur. J. Endocrinol.<\/i>, <b>148<\/b>, 293\u2013300 (2003).","DOI":"10.1530\/eje.0.1480293"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y, Takakuwa K, Matsui J, Takata M, Eto K, Terauchi Y, Komeda K, Tsunoda M, Murakami K, Ohnishi Y, Naitoh T, Yamamura K, Ueyama Y, Froguel P, Kimura S, Nagai R, Kadowaki T. Globular adiponectin protected ob\/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. <i>J. Biol. Chem.<\/i>, <b>278<\/b>, 2461\u20132468 (2003).","DOI":"10.1074\/jbc.M209033200"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Uysal OK, Sahin DY, Duran M, Turkoglu C, Yildirim A, Elbasan Z, Ozkan B, Tekin K, Kunak AU, Yilmaz Y, Kaya MG, Gur M, Cayli M. Association between uric acid and coronary collateral circulation in patients with stable coronary artery disease. <i>Angiology<\/i>, <b>65<\/b>, 227\u2013231 (2014).","DOI":"10.1177\/0003319713500706"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Sezer S, Karakan S, Atesagaoglu B, Acar FN. Allopurinol reduces cardiovascular risks and improves renal function in pre-dialysis chronic kidney disease patients with hyperuricemia. <i>Saudi J. Kidney Dis. Transpl.<\/i>, <b>25<\/b>, 316\u2013320 (2014).","DOI":"10.4103\/1319-2442.128520"},{"key":"25","unstructured":"25) Higgins P, Walters MR, Murray HM, McArthur K, McConnachie A, Lees KR, Dawson J. Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial. <i>Heart<\/i>, <b>100<\/b>, 1085\u20131092 (2014)."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Grimaldi-Bensouda L, Alp\u00e9rovitch A, Aubrun E, Danchin N, Rossignol M, Abenhaim L, Richette P, Fromage P, Furber A, Mery D, Jabali AE, Banos J-L, Tarabbia P, Sedighian S, Lallemant R, Kadri A, Ovize M, Saint-Mezard G, Brandstatt P, Koujan B, Amonchot A, Gouvion T, Ouanes K, Cottin Y, Zaouali H, Dormagen V, Afif Z, Godenir JP, Alary JP, Pierrard B, Imianitoff M, Bessede G, Vaquette B, Martelet M, Mouallem J, Sader R, Gorka H, Rosak P, Viallet M, Mokaddem J, Brefort G, Dahmani N, Nallet O, Guillot P, Leclercq F, Jamon Y, Tcheng E, Dibon O, Chaib A, Lozinguez O, Steg G, Delarche N, Boureux C, Merle E, Boukhsibi F, Rivet CM, Broin P, Boulain L, Ferron B, Hajmoussa E, Pradies F, Destrac S, Prouteau N, Heiligenstein D, Galinier M, Banayan J, Goburdhun C, Dobocan Craciun A, Zylberberg M, Gueranger P, the PGRx MI Group. Impact of allopurinol on risk of myocardial infarction. <i>Ann. Rheum. Dis.<\/i> <b>2014<\/b>, 202972 (2014).","DOI":"10.1136\/annrheumdis-2012-202972"},{"key":"27","unstructured":"27) Kok VC, Horng JT, Chang WS, Hong YF, Chang TH. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study. <i>PLoS ONE<\/i>, <b>9<\/b>, e99102 (2014)."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Okuda C, Koyama H, Tsutsumi Z, Yamamoto A, Kurajoh M, Moriwaki Y, Yamamoto T. Serum CRP in patients with gout and effects of benzbromarone. <i>Int. J. Clin. Pharmacol. Ther.<\/i>, <b>49<\/b>, 191\u2013197 (2011).","DOI":"10.5414\/CP201425"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/37\/12\/37_b14-00201\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T14:49:15Z","timestamp":1650725355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/37\/12\/37_b14-00201\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b14-00201","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}